Inhibitory effect of matrine on blood-brain barrier disruption for the treatment of experimental autoimmune encephalomyelitis

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Zhang, Su ^a   Kan, Quan Cheng ^a   Xu, Yuming ^a   Zhang, Guang Xian ^b   Zhu, Lin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; DEXAMETHASONE; GELATINASE A; GELATINASE B; MATRINE; ALKALOID; MMP2 PROTEIN, RAT; MMP9 PROTEIN, RAT; PROTEIN ZO1; QUINOLIZINE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TJP1 PROTEIN, RAT;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASEMENT MEMBRANE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; EXPERIMENTAL MODEL; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THERAPY EFFECT; ANIMAL; BODY WEIGHT; DRUG EFFECT; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY; WISTAR RAT;

ALKALOIDS; ANIMALS; BASEMENT MEMBRANE; BLOOD-BRAIN BARRIER; BODY WEIGHT; COLLAGEN TYPE IV; DEXAMETHASONE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; INFLAMMATION; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MULTIPLE SCLEROSIS; QUINOLIZINES; RATS; RATS, WISTAR; TISSUE INHIBITOR OF METALLOPROTEINASE-2; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84884873370     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/736085     Document Type: Article

References (44)

1. Rommer P. S., Stüve O., Management of secondary progressive multiple sclerosis: prophy- lactic treatment-past, present, and future aspect. Current Treatment Options in Neurology 2013 15 3 241 258
2. Lassmann H., Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models. Experimental Neurology 2010 225 1 2 8 2-s2.0-77955656367 10.1016/j.expneurol.2009.10.009
3. Badawi A. H., Kiptoo P., Wang W.-T., Choi I.-Y., Lee P., Vines C. M., Siahaan T. J., Suppression of EAE and prevention of blood-brain barrier breakdown after vaccination with novel bifunctional peptide inhibitor. Neuropharmacology 2012 62 4 1874 1881 2-s2.0-84856411455 10.1016/j.neuropharm. 2011.12.013
4. Pfeiffer F., Schäfer J., Lyck R., Makrides V., Brunner S., Schaeren-Wiemers N., Deutsch U., Engelhardt B., Claudin-1 induced sealing of blood-brain barrier tight junctions ameliorates chronic experimental autoimmune encephalomyelitis. Acta Neuropathologica 2011 122 5 601 614 2-s2.0-82355190262 10.1007/s00401-011-0883-2
5. Sorokin L., The impact of the extracellular matrix on inflammation. Nature Reviews Immunology 2010 10 10 712 723 2-s2.0-77957221743 10.1038/nri2852
6. Agrawal S., Anderson P., Durbeej M., Van Rooijen N., Ivars F., Opdenakker G., Sorokin L. M., Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. Journal of Experimental Medicine 2006 203 4 1007 1019 2-s2.0-33645869560 10.1084/jem.20051342
7. Hawkins B. T., Davis T. P., The blood-brain barrier/neurovascular unit in health and disease. Pharmacological Reviews 2005 57 2 173 185 2-s2.0-22944483792 10.1124/pr.57.2.4 (Pubitemid 41043883)
8. Hamann G. F., Liebetrau M., Martens H., Burggraf D., Kloss C. U. A., Bültemeier G., Wunderlich N., Jäger G., Pfefferkorn T., Microvascular basal lamina injury after experimental focal cerebral ischemia and reperfusion in the rat. Journal of Cerebral Blood Flow & Metabolism 2002 22 5 526 533 (Pubitemid 34477774)
9. Sehba F. A., Mostafa G., Knopman J., Friedrich V. Jr., Bederson J. B., Acute alterations in microvascular basal lamina after subarachnoid hemorrhage. Journal of Neurosurgery 2004 101 4 633 640 2-s2.0-7944234917 10.3171/jns.2004.101.4.0633 (Pubitemid 43186422)
10. Liu J., Jin X., Liu K. J., Liu W., Matrix metalloproteinase-2-mediated occludin degradation and caveolin-1-mediated claudin-5 redistribution contribute to blood-brain barrier damage in early ischemic stroke stage. Journal of Neuroscience 2012 32 9 3044 3057 2-s2.0-84857530337 10.1523/JNEUROSCI.6409-11. 2012
11. Khan M., Dhammu T. S., Sakakima H., Shunmugavel A., Gilg A. G., Singh A. K., Singh I., The inhibitory effect of S-nitroso-glutathione on blood-brain barrier disruption and peroxynitrite formation in a rat model of experimental stroke. Journal of Neurochemistry 2012 123 2 86 97
12. Bennett J., Basivireddy J., Kollar A., Biron K. E., Reickmann P., Jefferies W. A., McQuaid S., Blood-brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE. Journal of Neuroimmunology 2010 229 1-2 180 191 2-s2.0-78650185098 10.1016/j.jneuroim.2010. 08.011
13. Gold S. M., Sasidhar M. V., Morales L. B., Du S., Sicotte N. L., Tiwari-Woodruff S. K., Voskuhl R. R., Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through estrogen receptor alpha (ER α). Laboratory Investigation 2009 89 10 1076 1083 2-s2.0-70349559752 10.1038/labinvest.2009.79
14. Kandagaddala L. D., Kang M.-J., Chung B. C., Patterson T. A., Kwon O.-S., Expression and activation of matrix metalloproteinase-9 and NADPH oxidase in tissues and plasma of experimental autoimmune encephalomyelitis in mice. Experimental and Toxicologic Pathology 2012 64 1-2 109 114 2-s2.0-84857647125 10.1016/j.etp.2010.07.002
15. Clark A. W., Krekoski C. A., Bou S.-S., Chapman K. R., Edwards D. R., Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neuroscience Letters 1997 238 1-2 53 56 2-s2.0-0031459856 10.1016/S0304-3940(97)00859-8 (Pubitemid 28015782)
16. Ma X., Jiang Y., Wu A., Chen X., Pi R., Liu M., Liu Y., Berberine attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice. PLoS One 2010 5 10 2-s2.0-78149420304 10.1371/journal.pone.0013489 e13489
17. Avolio C., Filippi M., Tortorella C., Rocca M. A., Ruggieri M., Agosta F., Tomassini V., Pozzilli C., Stecchi S., Giaquinto P., Livrea P., Trojano M., Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Multiple Sclerosis 2005 11 4 441 446 2-s2.0-22144466188 10.1191/1352458505ms1193oa (Pubitemid 40984239)
18. Thorne M., Moore C. S., Robertson G. S., Lack of TIMP-1 increases severity of experimental autoimmune encephalomyelitis: effects of darbepoetin alfa on TIMP-1 null and wild-type mice. Journal of Neuroimmunology 2009 211 1-2 92 100 2-s2.0-67349181321 10.1016/j.jneuroim.2009.04.003
19. Lambert E., Dassé E., Haye B., Petitfrère E., TIMPs as multifacial proteins. Critical Reviews in Oncology/Hematology 2004 49 3 187 198 2-s2.0-1342279517 10.1016/j.critrevonc.2003.09.008 (Pubitemid 38251351)
20. Tency I., Verstraelen H., Kroes I., Holtappels G., Verhasselt B., Vaneechoutte M., Verhelst R., Temmerman M., Imbalances between matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) in maternal serum during preterm labor. PLoS One 2012 7 11 e49042
21. Lee W. H., Warrington J. P., Sonntag W. E., Lee Y. W., Irradiation alters MMP-2/TIMP-2 system and collagen type IV degradation in brain. International Journal of Radiation Oncology Biology Physics 2012 82 5 1559 1566 2-s2.0-84858678903 10.1016/j.ijrobp.2010.12.032
22. Kan Q. C., Zhu L., Liu N., Zhang G. X., Matrine suppresses expression of adhesion molecules and chemokines as a mechanism underlying its therapeutic effect in CNS autoimmunity. Immunologic Research 2013 56 1 189 196
23. Zhao X., Kan Q., Zhu L., Zhang G.-X., Matrine suppresses production of IL-23/IL-17 and ameliorates experimental autoimmune encephalomyelitis. American Journal of Chinese Medicine 2011 39 5 933 941 2-s2.0-80052642615 10.1142/S0192415X11009317
24. Zhang L., Wang T., Wen X., Wei Y., Peng X., Li H., Wei L., Effect of matrine on HeLa cell adhesion and migration. European Journal of Pharmacology 2007 563 1-3 69 76 2-s2.0-34247128303 10.1016/j.ejphar.2007.01.073 (Pubitemid 46602230)
25. Wang Z., Zhang J., Wang Y., Xing R., Yi C., Zhu H., Chen X., Guo J., Guo W., Li W., Wu L., Lu Y., Liu S., Matrine, a novel autophagy inhibitor, blocks trafficking and the proteolytic activation of lysosomal proteases. Carcinogenesis 2013 34 1 128 138
26. Huang X. N., Fu J., Wang W. Z., The effects of fasudil on the permeability of the rat blood-brain barrier and blood-spinal cord barrier following experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 2011 239 1-2 61 67 2-s2.0-80054953599 10.1016/j.jneuroim.2011.08.015
27. Fernández-López D., Faustino J., Daneman R., Zhou L., Lee S. Y., Derugin N., Wendland M. F., Vexler Z. S., Blood-brain barrier permeability is increased after acute adult stroke but not neonatal stroke in the rat. The Journal of Neuroscience 2012 32 28 9588 9600
28. Lee W. H., Warrington J. P., Sonntag W. E., Lee Y. W., Irradiation alters MMP-2/TIMP-2 system and collagen type IV degradation in brain. International Journal of Radiation Oncology Biology Physics 2012 82 5 1559 1566 2-s2.0-84858678903 10.1016/j.ijrobp.2010.12.032
29. Thal S. C., Luh C., Schaible E. V., Timaru-Kast R., Hedrich J., Luhmann H. J., Engelhard K., Zehendner C. M., Volatile anesthetics influence blood-brain barrier integrity by modulation of tight junction protein expression in traumatic brain injury. PLoS One 2012 7 12 e50752
30. Fabis M. J., Scott G. S., Kean R. B., Koprowski H., Hooper D. C., Loss of blood-brain barrier integrity in the spinal cord is common to experimental allergic encephalomyelitis in knockout mouse models. Proceedings of the National Academy of Sciences of the United States of America 2007 104 13 5656 5661 2-s2.0-34248355132 10.1073/pnas.0701252104 (Pubitemid 47175736)
31. Wosik K., Cayrol R., Dodelet-Devillers A., Berthelet F., Bernard M., Moumdjian R., Bouthillier A., Reudelhuber T. L., Prat A., Angiotensin II controls occludin function and is required for blood-brain barrier maintenance: relevance to multiple sclerosis. Journal of Neuroscience 2007 27 34 9032 9042 2-s2.0-34548145190 10.1523/JNEUROSCI.2088-07.2007 (Pubitemid 47312066)
32. Yang D. H., Ye Z. Y., Xie Y. J., He X. J., Xu W. J., Zhou W. M., Effect of salvianolate on intestinal epithelium tight junction protein zonula occludens protein 1 in cirrhotic rats. World Journal of Gastroenterology 2012 18 47 7040 7047
33. Bennett J., Basivireddy J., Kollar A., Biron K. E., Reickmann P., Jefferies W. A., McQuaid S., Blood-brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE. Journal of Neuroimmunology 2010 229 1-2 180 191 2-s2.0-78650185098 10.1016/j.jneuroim.2010. 08.011
34. Rosenberg G. A., Matrix metalloproteinases and neuroinflammation in multiple sclerosis. Neuroscientist 2002 8 6 586 595 2-s2.0-0036892580 10.1177/1073858402238517 (Pubitemid 35379453)
35. Sternlicht M. D., Werb Z., How matrix metalloproteinases regulate cell behavior. Annual Review of Cell and Developmental Biology 2001 17 463 516 2-s2.0-0035188727 10.1146/annurev.cellbio.17.1.463 (Pubitemid 33096184)
36. Yang Y., Estrada E. Y., Thompson J. F., Liu W., Rosenberg G. A., Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. Journal of Cerebral Blood Flow and Metabolism 2007 27 4 697 709 2-s2.0-33947493391 10.1038/sj.jcbfm.9600375 (Pubitemid 46474608)
37. Bauer A. T., Bürgers H. F., Rabie T., Marti H. H., Matrix metalloproteinase-9 mediates hypoxia-induced vascular leakage in the brain via tight junction rearrangement. Journal of Cerebral Blood Flow and Metabolism 2010 30 4 837 848 2-s2.0-77950516409 10.1038/jcbfm.2009.248
38. Jovanova-Nesic K., Shoenfeld Y., MMP-2, VCAM-1 and NCAM-1 expression in the brain of rats with experimental autoimmune encephalomyelitis as a trigger mechanism for synaptic plasticity and pathology. Journal of Neuroimmunology 2006 181 1-2 112 121 2-s2.0-33751541414 10.1016/j.jneuroim.2006.08.013 (Pubitemid 44834420)
39. Opdenakker G., Nelissen I., Van Damme J., Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurology 2003 2 12 747 756 2-s2.0-0344420053 10.1016/S1474-4422(03) 00587-8 (Pubitemid 37443517)
40. Sellner J., Simon F., Meyding-Lamade U., Leib S. L., Herpes-simplex virus encephalitis is characterized by an early MMP-9 increase and collagen type IV degradation. Brain Research 2006 1125 1 155 162 2-s2.0-33751504327 10.1016/j.brainres.2006.09.093 (Pubitemid 44838553)
41. Dore R. K., How to prevent glucocorticoid-induced osteoporosis. Cleveland Clinic Journal of Medicine 2010 77 8 529 536 2-s2.0-77956554535 10.3949/ccjm.77a.10003
42. Gennari C., Differential effect of glucocorticoids on calcium absorption and bone mass. British Journal of Rheumatology 1993 32 2 11 14 2-s2.0-0027263864 (Pubitemid 23179589)
43. Leow M. K.-S., Kwek D. S.-K., Ng A. W.-K., Ong K.-C., Kaw G. J.-L., Lee L. S.-U., Hypocortisolism in survivors of severe acute respiratory syndrome (SARS). Clinical Endocrinology 2005 63 2 197 202 2-s2.0-23244461359 10.1111/j.1365-2265.2005.02325.x (Pubitemid 41097989)
44. Minagar A., Maghzi A. H., McGee J. C., Alexander J. S., Emerging roles of endothelial cells in multiple sclerosis pathophysiology and therapy. Neurological Research 2012 34 8 738 745